* Adaptive Biotechnologies Corp reported a quarterly adjusted loss of 22 cents per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -35 cents. The mean expectation of eight analysts for the quarter was for a loss of 29 cents per share. Wall Street expected results to range from -35 cents to -24 cents per share.
* Revenue rose 22.5% to $46.44 million from a year ago; analysts expected $40.21 million.
* Adaptive Biotechnologies Corp's reported EPS for the quarter was a loss of 22 cents.
* The company reported a quarterly loss of $32.05 million.
* Adaptive Biotechnologies Corp shares had risen by 10.0% this quarter and gained 14.9% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had fallen by about 0.4% in the last three months.
* In the last 30 days, one analyst negatively revised an earnings estimate
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology & medical research peer group is also "buy"
Wall Street's median 12-month price target for Adaptive Biotechnologies Corp is $7.00 This summary was machine generated from LSEG data November 8 at 09:06 p.m. UTC. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2024 -0.29 -0.22 Beat
Jun. 30 2024 -0.33 -0.31 Beat
Mar. 31 2024 -0.34 -0.33 Beat
Dec. 31 2023 -0.33 -0.30 Beat
Comments